Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
Union Minister of State for Science and Technology, Dr Jitendra Singh gave the award for the successful commercialization of indigenous technology on National Technology Day 2022
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
This newly designed small-format detector is made up of caesium iodide technology and is extremely high in resolution, capable of capturing the fine detail of smaller anatomical structures present in paediatric patients
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
Subscribe To Our Newsletter & Stay Updated
